Results from a large cohort study indicate that a proportion of stage pT1b-pT2a melanoma patients could potentially avoid entinel lymph node biopsy (SLNB).
“The results of this large cohort study would suggest that, with the new modern treatment paradigm, a proportion of pT1b-pT2a patients could potentially avoid SLNB, since the management of these patients may remain unchanged, regardless of sentinel node status,” said lead study author Marc Moncrieff, MD, FRCS, a plastic surgeon